Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21660
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75. doi: 10.1016/S0140-6736(17)33326-3
- Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. [Survival of cancer patients]. [Slovenian]. Ljubljana; Institute of Oncology; 2020
- Montagne F, Guisier F, Venissac N, Baste JM. The role of surgery in lung cancer treatment: present indications and future perspectives – state of the art. Cancers 2021; 13: 1-24. doi: 10.3390/cancers13153711
- Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol 2021; 32: 1637-42. doi: 10.1016/J.ANNONC.2021.08.1994
- Shukla N, Hanna N. Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer. Lung Cancer Targets Ther 2021; 12: 51-60. doi: 10.2147/LCTT.S277717
- The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365: 395-409. doi: 10.1056/NEJMOA1102873/SUPPL_FILE/NEJMOA1102873_DISCLOSURES.PDF
- de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382: 503-13. doi: 10.1056/nejmoa1911793
- Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. doi: 10.1016/j.jtho.2015.09.009
- Taber S, Pfannschmidt J. Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients. Innov Surg Sci 2020; 5: 1-9.doi: 10.1515/iss-2020-0010
- Cai B, Fulcher N, Boyd M, Spira A. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: a real-world retrospective observational study. Thorac Cancer 2021; 12: 2055-64. doi: 10.1111/1759-7714.14007
- Abrão FC, Moreira FR, de Abreu IRLB, Marciano MG, Younes RN. Real-life long-term cohort of patients with stage IIIA non-small-cell lung cancer: overall survival related to patients’ characteristics and multiple treatment models. JCO Glob Oncol 2021; 7: 1572-85. doi: 10.1200/go.21.00219
- Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, et al. The significance of upfront knowledge of N2 disease in non-small cell lung cancer. World J Surg 2018; 42: 161-71. doi: 10.1007/s00268-017-4165-6
- Yun JK, Bok JS, Lee GD, Kim HR, Kim YH, Kim DK, et al. Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer. Eur J Cardio-Thoracic Surg 2020; 58: 59-69. doi: 10.1093/ejcts/ezaa042
- Crinò L, Weder W, van Meerbeeck J, Felip, ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v103-15. doi: 10.1093/annonc/mdq207
- Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felip E, et al.; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6:) vi89-98. doi: 10.1093/annonc/mdt241
- Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097/JTO.0b013e31812f3c1a
- Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014; 25: 1681-90. doi: 10.1093/annonc/mdu145
- Heineman DJ, Beck N, Wouters MW, van Brakel TJ, Daniels JM, Schreuers WH, et al. The dutch national clinical audit for lung cancer: a tool to improve clinical practice? An analysis of unforeseen ipsilateral mediastinal lymph node involvement in the Dutch Lung Surgery Audit (DLSA). Eur J Surg Oncol 2018; 44: 830-4. doi: 10.1016/J.EJSO.2017.12.002
- Debevec L, Jerič T, Kovač V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53. doi: 10.2478/V10019-009-0008-X
- Zwitter M, Čufer T, Vrankar M, Kern I, Štupnik T, Rozman A, et al. Lung Cancer in Slovenia. J Thorac Oncol 2019; 14: 1327-31. doi: 10.1016/J.JTHO.2019.02.025
- Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett 2013; 6: 1507-13. doi: 10.3892/ol.2013.1566
- Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004; 78: 209-15. doi: 10.1016/J.ATHORACSUR.2003.11.021.
- Saw SPL, Zhou S, Chen J, Lai G, Ang MK, Chua K, et al. Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer. JAMA Netw Open 2021; 4: e2131892. doi: 10.1001/jamanetworko-pen.2021.31892
- Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, et al. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: the INSIGHT study. J Thorac Oncol 2015; 10: 1370-4. doi: 10.1097/JTO.0000000000000621
- Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 2018; 18: 269. doi: 10.1186/s12885-018-4023-4
Language: English
Page range: 346 - 354
Submitted on: May 17, 2022
Accepted on: Jun 10, 2022
Published on: Aug 14, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2022 Marko Bitenc, Tanja Cufer, Izidor Kern, Martina Miklavcic, Sabrina Petrovic, Vida Groznik, Aleksander Sadikov, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.